| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | EAR1; hRev; THRA1; THRAL; ear-1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human NR1D1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于Caspase 3抗体的经典文献概览(基于公开信息整理)：
---
1. **文献名称**：*The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme*
**作者**：Yuan J, et al.
**摘要**：首次发现线虫凋亡基因ced-3编码的蛋白与哺乳动物Caspase家族(包括Caspase 3)同源，为后续抗体开发提供理论依据。研究揭示了Caspase在细胞凋亡中的保守性。
2. **文献名称**：*In vitro activation of CPP32 and Mch3 by Mch4. a novel human apoptotic cysteine protease containing two FADD-like domains*
**作者**：Fernandes-Alnemri T, et al.
**摘要**：通过Caspase 3抗体(如抗CPP32抗体)在Western blot中验证其酶原(32 kDa)及活性片段(17/12 kDa)，阐明了Caspase级联活化机制，为凋亡检测提供工具支持。
3. **文献名称**：*Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis*
**作者**：Nicholson DW, et al.
**摘要**：开发特异性Caspase 3抗体，用于检测其在凋亡细胞中的激活状态，证实其底物PARP的切割是凋亡标志事件，推动相关抗体在疾病模型中的应用。
4. **文献名称**：*Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor (DFF-45)*
**作者**：Porter AG, Jänicke RU.
**摘要**：利用Caspase 3抗体证明其直接激活DFF-45导致DNA断裂，确立Caspase 3在凋亡执行阶段的核心地位，为癌症和神经退行性疾病研究提供关键实验依据。
---
**注**：以上文献发表于1994-1999年，均为Caspase研究领域的奠基性工作。如需近年文献或具体抗体货号的应用文献，建议在PubMed或Web of Science中检索关键词“Caspase 3 antibody”。
Caspase 3. a member of the cysteine-aspartic acid protease (caspase) family, is a key executor of apoptosis (programmed cell death). It exists as an inactive zymogen (procaspase-3) that undergoes proteolytic cleavage into active subunits (p17 and p12) during apoptotic signaling. Caspase 3 antibodies are essential tools for detecting and quantifying both the inactive precursor (35-38 kDa) and active cleaved forms (17 kDa and 12 kDa) in various experimental settings, including Western blotting, immunohistochemistry, and flow cytometry. These antibodies enable researchers to study apoptosis dynamics in physiological processes (e.g., development, tissue homeostasis) and pathological conditions such as cancer, neurodegenerative diseases, and ischemic injuries.
Monoclonal and polyclonal Caspase 3 antibodies target specific epitopes, with some distinguishing between the pro-form and cleaved active form. Validation methods (e.g., knockout cell controls) are critical to confirm antibody specificity, as cross-reactivity with other caspases (e.g., Caspase 7) may occur. In translational research, Caspase 3 activation is monitored to assess therapeutic efficacy of pro-apoptotic drugs or to evaluate unintended cytotoxic effects. Its role as a biomarker in clinical samples (e.g., tumor biopsies) also highlights diagnostic and prognostic applications. Overall, Caspase 3 antibodies remain indispensable for unraveling apoptotic mechanisms and advancing biomedical research.
×
